2023
Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID‐19 Global Rheumatology Alliance Registry
Yazdany J, Ware A, Wallace Z, Bhana S, Grainger R, Hachulla E, Richez C, Cacoub P, Hausmann J, Liew J, Sirotich E, Jacobsohn L, Strangfeld A, Mateus E, Hyrich K, Gossec L, Carmona L, Lawson‐Tovey S, Kearsley‐Fleet L, Schaefer M, Ribeiro S, Al‐Emadi S, Hasseli R, Müller‐Ladner U, Specker C, Schulze‐Koops H, Bernardes M, Fraga V, Rodrigues A, Sparks J, Ljung L, Di Giuseppe D, Tidblad L, Wise L, Duarte‐García A, Ugarte‐Gil M, Colunga‐Pedraza I, Martínez‐Martínez M, Alpizar‐Rodriguez D, Xavier R, Isnardi C, Pera M, Pons‐Estel G, Izadi Z, Gianfrancesco M, Carrara G, Scirè C, Zanetti A, Machado P. Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID‐19 Global Rheumatology Alliance Registry. Arthritis Care & Research 2023, 76: 274-287. PMID: 37643903, DOI: 10.1002/acr.25220.Peer-Reviewed Original ResearchB-cell depleting therapySevere COVID-19Rheumatic diseasesCOVID-19 outcomesUnvaccinated peopleRisk factorsWorse outcomesCOVID-19Severe COVID-19 outcomesTumor necrosis factor inhibitorsHigh disease activityNecrosis factor inhibitorsConnective tissue diseaseCOVID-19 severityCOVID-19 vaccineThird of individualsLogistic regression modelsCOVID-19 diagnosisOrdinal logistic regression modelsLow HDI regionsMore comorbiditiesUnvaccinated patientsDisease activityUnvaccinated individualsFactor inhibitorsOmicron variant infection in inflammatory rheumatological conditions – outcomes from a COVID-19 naive population in Aotearoa New Zealand
Brooks J, Montgomery A, Dalbeth N, Sapsford M, Kee R, Cooper A, Quincey V, Bhana S, Gore-Massy M, Hausmann J, Liew J, Machado P, Sufka P, Sirotich E, Robinson P, Wallace Z, Yazdany J, Grainger R. Omicron variant infection in inflammatory rheumatological conditions – outcomes from a COVID-19 naive population in Aotearoa New Zealand. The Lancet Regional Health - Western Pacific 2023, 38: 100843. PMID: 37520279, PMCID: PMC10372177, DOI: 10.1016/j.lanwpc.2023.100843.Peer-Reviewed Original ResearchInflammatory rheumatic diseasesSARS-CoV-2 infectionHospitalisation/deathOmicron variant infectionConnective tissue diseaseRheumatic diseasesVariant infectionCOVID-19SARS-CoV-2 Omicron variantSingle vaccine doseCOVID-19 hospitalisationMultivariable adjusted modelsCOVID-19 vaccination statusMultivariable logistic regressionCOVID-19 vaccinationHigh vaccination ratesRituximab useVaccine doseInflammatory arthritisVaccination statusClinical factorsTissue diseaseDisease characteristicsVaccination ratesRisk factorsCharacteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
Machado P, Schäfer M, Mahil S, Liew J, Gossec L, Dand N, Pfeil A, Strangfeld A, Regierer A, Fautrel B, Alonso C, Saad C, Griffiths C, Lomater C, Miceli-Richard C, Wendling D, Rodriguez D, Wiek D, Mateus E, Sirotich E, Soriano E, Ribeiro F, Omura F, Martins F, Santos H, Dau J, Barker J, Hausmann J, Hyrich K, Gensler L, Silva L, Jacobsohn L, Carmona L, Pinheiro M, Zelaya M, de los Ángeles Severina M, Yates M, Dubreuil M, Gore-Massy M, Romeo N, Haroon N, Sufka P, Grainger R, Hasseli R, Lawson-Tovey S, Bhana S, Pham T, Olofsson T, Bautista-Molano W, Wallace Z, Yiu Z, Yazdany J, Robinson P, Smith C. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries. Annals Of The Rheumatic Diseases 2023, 82: 698-709. PMID: 36787993, PMCID: PMC10176347, DOI: 10.1136/ard-2022-223499.Peer-Reviewed Original ResearchConceptsSevere COVID-19High disease activityPandemic time periodDisease activityPsoriatic arthritisMale sexAxial spondyloarthritisCOVID-19Multivariable ordinal logistic regressionPoor COVID-19 outcomesOlder ageFuture respiratory pandemicsCOVID-19 severityCOVID-19 outcomesComorbidity burdenGlucocorticoid intakeGlucocorticoid useCancer comorbidityClinical characteristicsCOVID-19 waveRisk stratificationOrdinal logistic regressionReduced oddsSeverity ScaleRespiratory pandemic
2022
Obstetric outcomes in women with rheumatic disease and COVID-19 in the context of vaccination status
Maguire S, Al-Emadi S, Alba P, Aguiar M, Al Lawati T, Alle G, Bermas B, Bhana S, Branimir A, Bulina I, Clowse M, Cogo K, Colunga I, Cook C, Cortez K, Dao K, Gianfrancesco M, Gore-Massey M, Gossec L, Grainger R, Hausman J, Hsu T, Hyrich K, Isnardi C, Kawano Y, Kilding R, Kusevich D, Lawson-Tovey S, Liew J, McCarthy E, Montgumery A, Moyano S, Nasir N, Padjen I, Papagoras C, Patel N, Pera M, Pisoni C, Pons-Estel G, Quiambao A, Quintana R, Ruderman E, Sattui S, Savio V, Sciascia S, Sencarova M, Morales R, Siddique F, Sirotich E, Sparks J, Strangfeld A, Sufka P, Tanner H, Tissera Y, Wallace Z, Werner M, Wise L, Worthing A, Zell J, Zepa J, Machado P, Yazdany J, Robinson P, Conway R. Obstetric outcomes in women with rheumatic disease and COVID-19 in the context of vaccination status. Rheumatology 2022, 62: 1621-1626. PMID: 36124987, PMCID: PMC11181869, DOI: 10.1093/rheumatology/keac534.Peer-Reviewed Original ResearchConceptsObstetric outcomesPreterm birthVaccination statusPregnant womenUnvaccinated womenCOVID-19Exact testCOVID-19 vaccination statusCOVID-19 vaccine dosesCOVID-19 vaccinationCOVID-19 infectionFisher's exact testCOVID-19 diagnosisVaccine doseHospital admissionRheumatic diseasesMore dosesVaccine dosesPharmacological treatmentMusculoskeletal diseasesPregnancyDescriptive studyWomenOutcomesGreater numberProlonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
DiIorio M, Kennedy K, Liew JW, Putman MS, Sirotich E, Sattui SE, Foster G, Harrison C, Larché MJ, Levine M, Moni TT, Thabane L, Bhana S, Costello W, Grainger R, Machado PM, Robinson PC, Sufka P, Wallace ZS, Yazdany J, Gore-Massy M, Howard RA, Kodhek MA, Lalonde N, Tomasella LA, Wallace J, Akpabio A, Alpízar-Rodríguez D, Beesley RP, Berenbaum F, Bulina I, Chock EY, Conway R, Duarte-García A, Duff E, Gheita TA, Graef ER, Hsieh E, Kibbi L, Liew DF, Lo C, Nudel M, Singh AD, Singh JA, Singh N, Ugarte-Gil MF, Hausmann JS, Simard JF, Sparks JA. Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 2022, 8: e002587. PMID: 36104117, PMCID: PMC9475962, DOI: 10.1136/rmdopen-2022-002587.Peer-Reviewed Original ResearchConceptsSystemic autoimmune rheumatic diseasesCOVID-19 symptom durationSymptom durationAutoimmune rheumatic diseasesCOVID-19 onsetVaccines surveyRheumatic diseasesCOVID-19Test-confirmed COVID-19Complete symptom resolutionCOVID-19 severityCOVID-19 symptomsImmunomodulating medicationsComorbidity countSymptom resolutionBaseline characteristicsClinical characteristicsAcute symptomsVaccine dosesNovel viral variantsHigher oddsLower oddsDay 15Viral variantsLogistic regressionFactors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
Yeoh S, Gianfrancesco M, Lawson-Tovey S, Hyrich K, Strangfeld A, Gossec L, Carmona L, Mateus E, Schäfer M, Richez C, Hachulla E, Holmqvist M, Scirè C, Lorenz H, Voll R, Hasseli R, Jayatilleke A, Hsu T, D’Silva K, Pimentel-Quiroz V, del Mercado M, Shinjo S, dos Reis Neto E, da Rocha L, de Oliveira e Silva Montandon A, Pons-Estel G, Ornella S, Exeni M, Velozo E, Jordan P, Sirotich E, Hausmann J, Liew J, Jacobsohn L, Gore-Massy M, Sufka P, Grainger R, Bhana S, Wallace Z, Robinson P, Yazdany J, Machado P. Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. RMD Open 2022, 8: e002508. PMID: 36100295, PMCID: PMC9471207, DOI: 10.1136/rmdopen-2022-002508.Peer-Reviewed Original ResearchConceptsIdiopathic inflammatory myopathiesSevere COVID-19Prednisolone-equivalent doseHigh disease activityDisease activityInflammatory myopathiesMale sexSevere outcomesCOVID-19Multivariable ordinal logistic regressionOlder ageHigher comorbidity burdenLarge registry dataCOVID-19 diagnosisComorbidity burdenRituximab exposureClinical characteristicsRisk stratificationOrdinal logistic regressionRegistry dataHospitalisationSeverity ScaleDemographic dataLogistic regressionPatientsCharacteristics and Outcomes of People With Gout Hospitalized Due to COVID‐19: Data From the COVID‐19 Global Rheumatology Alliance Physician‐Reported Registry
Jatuworapruk K, Montgomery A, Gianfrancesco M, Conway R, Durcan L, Graef E, Jayatilleke A, Keen H, Kilian A, Young K, Carmona L, Cogo A, Duarte‐García A, Gossec L, Hasseli R, Hyrich K, Langlois V, Lawson‐Tovey S, Malcata A, Mateus E, Schafer M, Scirè C, Sigurdardottir V, Sparks J, Strangfeld A, Xavier R, Bhana S, Gore‐Massy M, Hausmann J, Liew J, Sirotich E, Sufka P, Wallace Z, Machado P, Yazdany J, Grainger R, Robinson P. Characteristics and Outcomes of People With Gout Hospitalized Due to COVID‐19: Data From the COVID‐19 Global Rheumatology Alliance Physician‐Reported Registry. ACR Open Rheumatology 2022, 4: 948-953. PMID: 36000538, PMCID: PMC9539246, DOI: 10.1002/acr2.11495.Peer-Reviewed Original ResearchMore comorbiditiesVentilatory supportPoor outcomeCOVID-19COVID-19-related deathsChronic kidney diseasePresence of comorbiditiesCohort of peopleCOVID-19 outcomesCoronavirus disease 2019Outcomes of peopleMedication exposureOverall cohortVentilation supportDiabetes mellitusSupplemental oxygenKidney diseaseMean ageRisk factorsCardiovascular diseaseDisease 2019ComorbiditiesGoutCohortPatientsEnvironmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study
Izadi Z, Gianfrancesco M, Schmajuk G, Jacobsohn L, Katz P, Rush S, Ja C, Taylor T, Shidara K, Danila M, Wysham K, Strangfeld A, Mateus E, Hyrich K, Gossec L, Carmona L, Lawson-Tovey S, Kearsley-Fleet L, Schaefer M, Al-Emadi S, Sparks J, Hsu T, Patel N, Wise L, Gilbert E, Duarte-García A, Valenzuela-Almada M, Ugarte-Gil M, Ljung L, Scirè C, Carrara G, Hachulla E, Richez C, Cacoub P, Thomas T, Santos M, Bernardes M, Hasseli R, Regierer A, Schulze-Koops H, Müller-Ladner U, Pons-Estel G, Tanten R, Nieto R, Pisoni C, Tissera Y, Xavier R, Marques C, Pileggi G, Robinson P, Machado P, Sirotich E, Liew J, Hausmann J, Sufka P, Grainger R, Bhana S, Gore-Massy M, Wallace Z, Yazdany J, Registry C, Dahou B, Gómez G, Roberts K, Baez R, Coello V, Salinas M, Maldonado F, Reyes A, Alle G, Tanten R, Ficco H, Nieto R, Gobbi C, Tissera Y, Pisoni C, Paula A, Albiero J, Schmid M, Cosatti M, Gamba M, Leandro C, Cusa M, German N, Bellomio V, Takashima L, Pera M, Cogo K, Elkin M, Medina M, Savio V, Tessel R, Alamino R, Werner M, Ornella S, Casalla L, de la Vega M, Severina M, García M, Lucero L, Romeo C, Moyano S, Barbich T, Bertoli A, Baños A, Petruzzelli S, Matellan C, Conti S, Lazaro M, Gil G, Risueño F, Quaglia M, Scafati J, Cuchiaro N, Rebak J, Pineda S, Calvo M, Picco E, Yanzi J, Maid P, Guaglianone D, Morbiducci J, Porta S, Herscovich N, Zamora J, Kisluk B, Menescardi M, Gallo R, Martire M, Maldini C, Goizueta C, de la Vega Fernandez S, Aeschlimann C, Subils G, Rath E, Piette Y, Devinck M, Maeyaert B, Ribeiro F, Ribeiro S, Pinheiro M, Ibáñez S, Trubert A, Dong L, Cajas L, Barešić M, Anić B, Ćulo M, Pavelić T, Stranski K, Karanovic B, Vencovsky J, Píchová M, Filkova M, Hamoud H, Vassilopoulos D, Melgar G, So H, Király M, Vojdanian, Gurman A, Abutiban F, Zepa J, Bulina I, Bukauskiene L, Montiel B, Ortiz A, Tehozol E, Morales D, Rosete D, Nares E, Reyna T, Gabayet M, Rodríguez D, Irazoque F, Jimenez X, van Bon L, Zijlstra T, Hoekstra M, Al Adhoubi N, Salim B, Giraldo E, Salinas A, Gil M, Nowakowski J, Conway R, Flood R, McCarthy G, Felea I, Filipescu I, Rednic S, Groseanu L, Tamas M, Mlynarikova V, Skamlova M, Zlnay M, Mičeková D, Capova L, Macejova Z, Šteňová E, Raffayova H, Belakova G, Strakova E, Senčarová M, Žlnayová S, Sabová A, Spisakova D, Oetterová M, Lukacova O, Bakosova M, Hocevar A, de la Torre Rubio N, Sancho J, Coro M, Garcia J, Martin M, Campos J, Puerta J, Yardimci G, Akar S, Icacan O, ÇELİK S, Vasylets V, Yeoh S, Vandevelde C, Dunt S, Leeder J, Macphie E, Salerno R, Graver C, Williams K, O'Reilly S, Devine K, Tyler J, Warner E, Pilcher J, Patel S, Nikiphorou E, Chadwick L, Jones C, Harrison B, Thornton L, O'Kane D, Fusi L, Low A, Horton S, Jatwani S, Baig S, Bajwa H, Berglund V, Dahle A, Dorman W, Hargrove J, Hilton M, Lebedoff N, Leonard S, Morgan J, Pfeifer E, Skemp A, Wilson J, Wolff A, Cepeda E, Todd D, Hare D, Calabrese C, Adams C, Khosroshahi A, Kilian A, White D, Winter M, Fields T, Siegel C, Daver N, Harvey M, Kramer N, Lamore C, Hogarty S, Yeter K, Siddique F, Ban B, Tanner T, Ruderman E, Davis W, Quinet R, Scopelitis E, Toribio K, Detiege T, Zakem J, Abbass K, Kepecs G, Miranda L, Guma M, Haikal A, Mody S, Mueller D, Jayatilleke A, Zell J, Bays A, Dao K, Ezzati F, Parks D, Karp D, Quiceno G. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study. The Lancet Rheumatology 2022, 4: e603-e613. PMID: 35909441, PMCID: PMC9313519, DOI: 10.1016/s2665-9913(22)00192-8.Peer-Reviewed Original ResearchRheumatic diseasesCOVID-19 outcomesRisk factorsObservational studyCOVID-19COVID-19-related deathsClinical risk factorsMultivariable logistic regressionCOVID-19 severity levelsIndividual-level risk factorsPrimary endpointMean ageIndependent associationHigher oddsAmerican CollegeLower oddsLogistic regressionHospital bedsMortalityDiseaseSocietal factorsMixed effects modelsDeathRheumatologyAssociationSARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry
Liew J, Gianfrancesco M, Harrison C, Izadi Z, Rush S, Lawson-Tovey S, Jacobsohn L, Ja C, Hyrich K, Gossec L, Strangfeld A, Carmona L, Schäfer M, Frãzao-Mateus E, Bulina I, Stafford F, Tufan A, Graver C, Yardımcı G, Zepa J, Al Emadi S, Cook C, Abutiban F, Dey D, Katigbak G, Kaufman L, Kowalski E, Martínez-Martínez M, Patel N, Reyes-Cordero G, Salido E, Smith E, Snow D, Sparks J, Wise L, Bhana S, Gore-Massy M, Grainger R, Hausmann J, Sirotich E, Sufka P, Wallace Z, Machado P, Robinson P, Yazdany J. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. RMD Open 2022, 8: e002187. PMID: 35387864, PMCID: PMC8987210, DOI: 10.1136/rmdopen-2021-002187.Peer-Reviewed Original ResearchConceptsB-cell depleting therapyBreakthrough infectionsRheumatic diseasesSARS-CoV-2Clinical characteristicsSARS-CoV-2 breakthrough infectionsPre-existing lung diseaseSARS-CoV-2 infectionBreakthrough COVID-19Cell-depleting therapyTwo-dose seriesTime of vaccinationSecond vaccine doseHigh-risk populationMessenger RNA vaccinesCOVID-19 symptomsSingle-dose vaccineCOVID-19Vaccination seriesSystemic glucocorticoidsVaccine doseVaccine effectivenessSecond doseVaccinated individualsLung diseaseCharacteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance
Ugarte-Gil M, Alarcón G, Izadi Z, Duarte-García A, Reátegui-Sokolova C, Clarke A, Wise L, Pons-Estel G, Santos M, Bernatsky S, Ribeiro S, Al Emadi S, Sparks J, Hsu T, Patel N, Gilbert E, Valenzuela-Almada M, Jönsen A, Landolfi G, Fredi M, Goulenok T, Devaux M, Mariette X, Queyrel V, Romão V, Sequeira G, Hasseli R, Hoyer B, Voll R, Specker C, Baez R, Castro-Coello V, Ficco H, Neto E, Ferreira G, Monticielo O, Sirotich E, Liew J, Hausmann J, Sufka P, Grainger R, Bhana S, Costello W, Wallace Z, Jacobsohn L, Taylor T, Ja C, Strangfeld A, Mateus E, Hyrich K, Carmona L, Lawson-Tovey S, Kearsley-Fleet L, Schäfer M, Machado P, Robinson P, Gianfrancesco M, Yazdany J. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Annals Of The Rheumatic Diseases 2022, 81: 970-978. PMID: 35172961, PMCID: PMC8882632, DOI: 10.1136/annrheumdis-2021-221636.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusCOVID-19 outcomesSevere outcomesDisease activityLupus erythematosusHigher SLE disease activityActive systemic lupus erythematosusMultivariable ordinal logistic regression modelsSevere COVID-19 outcomesPoor COVID-19 outcomesSLE disease activitySex-adjusted modelsMore severe outcomesCOVID-19 severityCOVID-19Logistic regression modelsOrdinal logistic regression modelsPrednisone doseMale sexGlobal RegistryWorse outcomesMultivariable modelCurrent treatmentComorbiditiesOlder ageThe impact of COVID-19 on rheumatology training—results from the COVID-19 Global Rheumatology Alliance trainee survey
Young K, Yeoh S, Putman M, Sattui S, Conway R, Graef E, Kilian A, Konig M, Sparks J, Ugarte-Gil M, Upton L, Berenbaum F, Bhana S, Costello W, Hausmann J, Machado P, Robinson P, Sirotich E, Sufka P, Yazdany J, Liew J, Grainger R, Wallace Z, Jayatilleke A. The impact of COVID-19 on rheumatology training—results from the COVID-19 Global Rheumatology Alliance trainee survey. Rheumatology Advances In Practice 2022, 6: rkac001. PMID: 35392427, PMCID: PMC8982766, DOI: 10.1093/rap/rkac001.Peer-Reviewed Original ResearchRheumatology traineesCOVID-19Rheumatology trainingCoronavirus disease 2019 (COVID-19) pandemicDisease 2019 pandemicCOVID-19 pandemicOutpatient clinicInpatient consultationsClinical careClinical experiencePatient careWeb-based surveyPhysical healthTrainee surveyClinical learning environmentCareClinical work
2021
Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study
Sattui S, Conway R, Putman M, Seet A, Gianfrancesco M, Beins K, Hill C, Liew D, Mackie S, Mehta P, Neill L, Gomez G, Salinas M, Maldonado F, Mariz H, de Sousa Studart S, Araujo N, Knight A, Rozza D, Quartuccio L, Samson M, Bally S, Maria A, Chazerain P, Hasseli R, Müller-Ladner U, Hoyer B, Voll R, Torres R, Luis M, Ribeirio S, Al-Emadi S, Sparks J, Hsu T, D’Silva K, Patel N, Wise L, Gilbert E, Almada M, Duarte-García A, Ugarte-Gil M, Jacobsohn L, Izadi Z, Strangfeld A, Mateus E, Hyrich K, Gossec L, Carmona L, Lawson-Tovey S, Kearsley-Fleet L, Schaefer M, Sirotich E, Hausmann J, Sufka P, Bhana S, Liew J, Grainger R, Machado P, Wallace Z, Yazdany J, Robinson P, Alliance G, Dahou B, Rath E, Piette Y, Devinck M, Maeyaert B, Ribeiro F, Ribeiro S, Pinheiro M, Quintana R, Gómez G, Roberts K, Baez R, Coello V, Salinas M, Maldonado F, Torres A, Alle G, Tanten R, Ficco H, Nieto R, Gobbi C, Tissera Y, Pisoni C, Paula A, Albiero J, Schmid M, Cosatti M, Gamba M, Leandro C, Cusa M, German N, Bellomio V, Takashima L, Pera M, Cogo K, Elkin M, Medina M, Savio V, Tessel I, Alamino R, Werner M, Ornella S, Casalla L, de la Vega M, Severina M, García M, Lucero L, Romeo C, Moyano S, Barbich T, Bertoli A, Baños A, Petruzzelli S, Matellan C, Conti S, Lazaro M, Gil G, Risueño F, Quaglia M, Scafati J, Cuchiaro N, Rebak J, Pineda S, Calvo M, Picco E, Yanzi J, Maid P, Guaglianone D, Morbiducci J, Porta S, Herscovich N, Zamora J, Kisluk B, Menescardi M, Gallo R, Martire M, Maldini C, Goizueta C, de la Vega Fernandez S, Aeschlimann C, Subils G, Ibáñez S, Chassin-Trubert A, Dong L, Cajas L, Barešic M, Anic B, Culo M, Pavelic T, Stranski K, Karanovic B, Vencovsky J, Píchová M, Filkova M, Hamoud H, Vassilopoulos D, Melgar G, So H, Király M, Vojdanian, Balbir-Gurman A, Abutiban F, Zepa J, Bulina I, Bukauskiene L, Zaueta B, Ortiz A, Tehozol E, Vega D, Rosete D, Nares E, Rodriguez-Reyna T, Gabayet M, Alpízar-Rodríguez D, Irazoque F, Jimenez X, Bon L, Zijlstra T, Hoekstra M, Al-Adhoubi N, Salim B, Giraldo E, Salinas A, Ugarte-Gil M, Nowakowski J, Al-Emadi S, Conway R, Flood R, McCarthy G, Felea I, Filipescu I, Rednic S, Groseanu L, Tamas M, Mlynarikova V, Skamlova M, Zlnay M, Miceková D, Capova L, Macejova Z, Štenová E, Raffayova H, Belakova G, Strakova E, Sencarová M, Žlnayová S, Sabová A, Spisakova D, Oetterová M, Lukacova O, Bakosova M, Hocevar A, de la Torre-Rubio N, Sancho J, Coro M, Garcia J, Martin M, Campos J, Puerta J, Yardimci G, Akar S, Icacan O, Çelik S, Vasylets V, Yeoh S, Vandevelde C, Dunt S, Leeder J, Macphie E, Salerno R, Graver C, Williams K, O'Reilly S, Devine K, Tyler J, Warner E, Pilcher J, Patel S, Nikiphorou E, Chadwick L, Jones C, Harrison B, Thornton L, O'Kane D, Fusi L, Low A, Horton S, Jatwani S, Baig S, Bajwa H, Berglund V, Dahle A, Dorman W, Hargrove J, Hilton M, Lebedoff N, Leonard S, Morgan J, Pfeifer E, Skemp A, Wilson J, Wolff A, Cepeda E, D'Silva K, Hsu T, Patel N, Sparks J, Todd D, Wallace Z, Hare D, Calabrese C, Adams C, Khosroshahi A, Kilian A, White D, Winter M, Fields T, Siegel C, Daver N, Harvey M, Kramer N, Lamore C, Hogarty S, Yeter K, Wise L, Siddique F, Ban B, Tanner T, Ruderman E, Davis W, Quinet R, Scopelitis E, Toribio K, Webb-Detiege T, Zakem J, Abbass K, Kepecs G, Miranda L, Guma M, Haikal A, Mody S, Mueller D, Jayatilleke A, Zell J, Bays A, Dao K, Fatemeh E, Parks D, Karp D, Quiceno G. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. The Lancet Rheumatology 2021, 3: e855-e864. PMID: 34778843, PMCID: PMC8570701, DOI: 10.1016/s2665-9913(21)00316-7.Peer-Reviewed Original ResearchPrimary systemic vasculitisCOVID-19 outcomesPoor COVID-19 outcomesNumber of comorbiditiesRetrospective cohort studySystemic vasculitisPolymyalgia rheumaticaSupplemental oxygenDisease activityCohort studyRisk factorsOdds ratioMultivariable ordinal logistic regression analysisSevere COVID-19 outcomesHigh-dose glucocorticoidsLow disease activitySevere disease activityGiant cell arteritisUnmodifiable risk factorsLogistic regression analysisOrdinal logistic regression analysisCOVID-19Eligible patientsGlucocorticoid useMore comorbiditiesAssociation Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19
Izadi Z, Brenner E, Mahil S, Dand N, Yiu Z, Yates M, Ungaro R, Zhang X, Agrawal M, Colombel J, Gianfrancesco M, Hyrich K, Strangfeld A, Carmona L, Mateus E, Lawson-Tovey S, Klingberg E, Cuomo G, Caprioli M, Cruz-Machado A, Mazeda Pereira A, Hasseli R, Pfeil A, Lorenz H, Hoyer B, Trupin L, Rush S, Katz P, Schmajuk G, Jacobsohn L, Seet A, Al Emadi S, Wise L, Gilbert E, Duarte-García A, Valenzuela-Almada M, Isnardi C, Quintana R, Soriano E, Hsu T, D’Silva K, Sparks J, Patel N, Xavier R, Marques C, Kakehasi A, Flipo R, Claudepierre P, Cantagrel A, Goupille P, Wallace Z, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Robinson P, Machado P, Griffiths C, Barker J, Smith C, Yazdany J, Kappelman M, Bachelez H, Capon F, Coker B, De La Cruz C, Mason K, Di Meglio P, Gelfand J, Gisondi P, Iversen L, Jullien D, Lambert J, Langan S, McAteer H, Meynell F, Moorhead L, Naldi L, Puig L, Reynolds N, Spuls P, Torres T, Tsakok T, Vincent A, Warren R, Waweru H, Ng S, Gearry R, Reinisch W, Rahier J, Lewis J, Kaplan G, Steinwurz F, Kissous-Hunt M, Modesto I, Konings M, Dahou B, Gómez G, Roberts K, Baez R, Castro Coello V, Haye Salinas M, Maldonado F, Reyes A, Alle G, Tanten R, Maldonado Ficco H, Nieto R, Gobbi C, Tissera Y, Pisoni C, Paula A, Albiero J, Schmid M, Cosatti M, Gamba M, Leandro C, Cusa M, German N, Bellomio V, Takashima L, Pera M, Cogo K, Gálvez Elkin M, Medina M, Savio V, Rojas Tessel R, Alamino R, Werner M, Ornella S, Casalla L, de la Vega M, Severina M, García M, Gonzalez Lucero L, Romeo C, Moyano S, Barbich T, Bertoli A, Baños A, Petruzzelli S, Matellan C, Conti S, Lazaro M, Rodriguez Gil G, Risueño F, Quaglia M, Scafati J, Cuchiaro N, Rebak J, Pineda S, Calvo M, Picco E, Yanzi J, Maid P, Guaglianone D, Morbiducci J, Porta S, Herscovich N, Velasco Zamora J, Kisluk B, Castaños Menescardi M, Gallo R, Martire M, Maldini C, Goizueta C, de la Vega Fernandez S, Aeschlimann C, Subils G, Rath E, Piette Y, Devinck M, Maeyaert B, Machado Ribeiro F, Euzebio Ribeiro S, Pinheiro M, Ibáñez S, Chassin Trubert A, Dong L, Cajas L, Barešić M, Anić B, Čulo M, Pavelić T, Stranski K, Karanovic B, Vencovsky J, Píchová M, Filkova M, Hamoud H, Vassilopoulos D, Guzman Melgar G, So H, Király M, Vojdanian M, Balbir Gurman A, Abutiban F, Zepa J, Bulina I, Bukauskiene L, Zazueta Montiel B, Castillo Ortiz A, Zamora Tehozol E, Vega Morales D, Cervántes Rosete D, Martín Nares E, Rodriguez Reyna T, Rull Gabayet M, Alpízar Rodríguez D, Irazoque F, Jimenez X, Geurts van Bon L, Zijlstra T, Hoekstra M, Al Adhoubi N, Salim B, Giraldo E, Salinas A, Ugarte Gil M, Nowakowski J, Conway R, Flood R, McCarthy G, Felea I, Filipescu I, Rednic S, Groseanu L, Tamas M, Mlynarikova V, Skamlova M, Zlnay M, Mičeková D, Capova L, Macejova Z, Šteňová E, Raffayova H, Belakova G, Strakova E, Senčarová M, Žlnayová S, Sabová A, Spisakova D, Oetterová M, Lukacova O, Bakosova M, Hocevar A, de la Torre Rubio N, Alegre Sancho J, Corteguera Coro M, Cobeta Garcia J, Torres Martin M, Campos J, Gomez Puerta J, Yardımcı G, Akar S, Icacan O, ÇELİK S, Vasylets V, Yeoh S, Vandevelde C, Dunt S, Leeder J, Macphie E, Salerno R, Graver C, Williams K, O'Reilly S, Devine K, Tyler J, Warner E, Pilcher J, Patel S, Nikiphorou E, Chadwick L, Jones C, Harrison B, Thornton L, O'Kane D, Fusi L, Low A, Horton S, Jatwani S, Baig S, Bajwa H, Berglund V, Dahle A, Dorman W, Hargrove J, Hilton M, Lebedoff N, Leonard S, Morgan J, Pfeifer E, Skemp A, Wilson J, Wolff A, Cepeda E, Todd D, Hare D, Calabrese C, Adams C, Khosroshahi A, Kilian A, White D, Winter M, Fields T, Siegel C, Daver N, Harvey M, Kramer N, Lamore C, Hogarty S, Yeter K, Siddique F, Ban B, Tanner T, Ruderman E, Davis W, Quinet R, Scopelitis E, Toribio K, Webb Detiege T, Zakem J, Abbass K, Kepecs G, Miranda L, Guma M, Haikal A, Mody S, Mueller D, Jayatilleke A, Zell J, Bays A, Dao K, Ezzati F, Parks D, Karp D, Quiceno G. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Network Open 2021, 4: e2129639. PMID: 34661663, PMCID: PMC8524310, DOI: 10.1001/jamanetworkopen.2021.29639.Peer-Reviewed Original ResearchConceptsTNF inhibitor monotherapyCOVID-19-associated hospitalizationTumor necrosis factor inhibitorsNecrosis factor inhibitorsInhibitor monotherapyInflammatory bowel diseaseTNF inhibitorsCOVID-19 outcomesPooled analysisMethotrexate monotherapyImmunomodulatory treatmentMethotrexate therapyClinical characteristicsCohort studyBowel diseaseFactor inhibitorsInflammatory diseasesMAIN OUTCOMEAdverse COVID-19 outcomesCOVID-19Multivariable logistic regression modelMultilevel multivariable logistic regression modelsJAK inhibitor monotherapyKinase inhibitor monotherapyRisk of hospitalizationCOVID-19 in women with rheumatic disease who are pregnant: Data from the COVID-19 Global Rheumatology Alliance
Bermas B, Gianfrancesco M, Tanner H, Seet A, Aguiar M, Al Adhoubi N, Al Emadi S, Cunha B, Flood R, Kusevich D, McCarthy E, Patel N, Ruderman E, Sattui S, Sciascia S, Siddique F, Valenzuela-Almada M, Wise L, Worthing A, Zell J, Bhana S, Costello W, Duarte-Garcia A, Grainger R, Gossec L, Hausmann J, Hyrich K, Lawson-Tovey S, Liew J, Sirotich E, Sparks J, Sufka P, Wallace Z, Machado P, Strangfeld A, Clowse M, Yazdany J, Robinson P. COVID-19 in women with rheumatic disease who are pregnant: Data from the COVID-19 Global Rheumatology Alliance. The Journal Of Rheumatology 2021, 49: 110-114. PMID: 34470798, DOI: 10.3899/jrheum.210480.Peer-Reviewed Original ResearchConceptsRheumatic diseasesPregnant womenPregnancy outcomesObstetric detailsCOVID-19Combination of antimalarialsRheumatic disease diagnosisLopinavir/ritonavirSystemic lupus erythematosusCases of patientsCOVID-19 infectionCoronavirus disease 2019Time of infectionCOVID-19 diagnosisTime of reportAntiphospholipid syndromeInflammatory arthritidesPreterm birthLupus erythematosusMedian ageTerm birthsRheumatoid arthritisSupplemental oxygenArthritis/Medication treatmentAssociations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
Sparks J, Wallace Z, Seet A, Gianfrancesco M, Izadi Z, Hyrich K, Strangfeld A, Gossec L, Carmona L, Mateus E, Lawson-Tovey S, Trupin L, Rush S, Katz P, Schmajuk G, Jacobsohn L, Wise L, Gilbert E, Duarte-García A, Valenzuela-Almada M, Pons-Estel G, Isnardi C, Berbotto G, Hsu T, D’Silva K, Patel N, Kearsley-Fleet L, Schäfer M, Ribeiro S, Al Emadi S, Tidblad L, Scirè C, Raffeiner B, Thomas T, Flipo R, Avouac J, Seror R, Bernardes M, Cunha M, Hasseli R, Schulze-Koops H, Müller-Ladner U, Specker C, de Souza V, da Mota L, Gomides A, Dieudé P, Nikiphorou E, Kronzer V, Singh N, Ugarte-Gil M, Wallace B, Akpabio A, Thomas R, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Robinson P, Machado P, Yazdany J, Dahou B, Quintana R, Gómez G, Roberts K, Baez R, Coello V, Salinas M, Maldonado F, Reyes A, Alle G, Tanten R, Ficco H, Nieto R, Gobbi C, Tissera Y, Pisoni C, Paula A, Albiero J, Schmid M, Cosatti M, Gamba M, Leandro C, Cusa M, German N, Bellomio V, Takashima L, Pera M, Cogo K, Elkin M, Medina M, Savio V, Tessel I, Alamino R, Werner M, Ornella S, Casalla L, de la Vega M, Severina M, García M, Lucero L, Romeo C, Moyano S, Barbich T, Bertoli A, Baños A, Petruzzelli S, Matellan C, Conti S, Lazaro M, Gil G, Risueño F, Quaglia M, Scafati J, Cuchiaro N, Rebak J, Pineda S, Calvo M, Picco E, Yanzi J, Maid P, Guaglianone D, Morbiducci J, Porta S, Herscovich N, Zamora J, Kisluk B, Menescardi M, Gallo R, Martire M, Maldini C, Goizueta C, de Fernandez S, Argentina C, Subils G, Rath E, Piette Y, Devinck M, Maeyaert B, Ribeiro F, Ribeiro S, Pinheiro M, Ibáñez S, Chassin-Trubert A, Dong L, Cajas L, Barešić M, Anić B, Čulo M, Pavelić T, Stranski K, Karanovic B, Vencovsky J, Píchová M, Filkova M, Hamoud H, Vassilopoulos D, Melgar G, So H, Király M, Vojdanian, Balbir-Gurman A, Abutiban F, Zepa J, Bulina I, Bukauskiene L, Zazueta-Montiel B, Castillo-Ortiz A, Zamora-Tehozol E, Vega-Morales D, Rosete D, Martín-Nares E, Rodriguez-Reyna T, Gabayet M, Alpízar-Rodríguez D, Irazoque F, Jimenez X, Bon L, Zijlstra T, Hoekstra M, Al-Adhoubi N, Salim B, Giraldo E, Salinas A, Ugarte-Gil M, Nowakowski J, Al-Emadi S, Conway R, Flood R, McCarthy G, Felea I, Filipescu I, Rednic S, Groseanu L, Tamas M, Mlynarikova V, Skamlova M, Zlnay M, Mičeková D, Capova L, Macejova Z, Šteňová E, Raffayova H, Belakova G, Strakova E, Senčarová M, Sabová A, Spisakova D, Oetterová M, Lukacova O, Bakosova M, Hocevar A, de la Torre-Rubio N, Sancho J, Coro M, Garcia J, Martin M, Campos J, Puerta J, Yardımcı G, Akar S, Icacan O, ÇELİK S, Vasylets V, Yeoh S, Vandevelde C, Dunt S, Leeder J, Macphie E, Salerno R, Graver C, Williams K, O'Reilly S, Devine K, Tyler J, Warner E, Pilcher J, Patel S, Nikiphorou E, Chadwick L, Jones C, Harrison B, Thornton L, O'Kane D, Fusi L, Low A, Horton S, Jatwani S, Baig S, Bajwa H, Berglund V, Dahle A, Dorman W, Hargrove J, Hilton M, Lebedoff N, Leonard S, Morgan J, Pfeifer E, Skemp A, Wilson J, Wolff A, Cepeda E, Todd D, Hare D, Calabrese C, Adams C, Khosroshahi A, Kilian A, White D, Winter M, Fields T, Siegel C, Daver N, Harvey M, Kramer N, Lamore C, Hogarty S, Yeter K, Wise L, Siddique F, Ban B, Tanner T, Ruderman E, Davis W, Quinet R, Scopelitis E, Toribio K, Webb-Detiege T, Zakem J, Abbass K, Kepecs G, Miranda L, Guma M, Haikal A, Mody S, Mueller D, Jayatilleke A, Zell J, Bays A, Dao K, Fatemeh E, Parks D, Karp D, Quiceno G. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Annals Of The Rheumatic Diseases 2021, 80: 1137-1146. PMID: 34049860, PMCID: PMC8172266, DOI: 10.1136/annrheumdis-2021-220418.Peer-Reviewed Original ResearchConceptsDisease-modifying antirheumatic drugsCOVID-19 severitySynthetic disease-modifying antirheumatic drugsWorse COVID-19 severityRheumatoid arthritisBaseline useCOVID-19 severity outcomeTumor necrosis factor inhibitorsInterleukin-6 inhibitorsNecrosis factor inhibitorsPotential baseline confoundersCOVID-19 outcomesPhysician registryCOVID-19IL-6iAntirheumatic drugsClinical onsetBaseline confoundersFactor inhibitorsOrdinal logistic regressionDrug classesRituximabAbataceptTNFiHospitalisationAssociation of Race and Ethnicity With COVID‐19 Outcomes in Rheumatic Disease: Data From the COVID‐19 Global Rheumatology Alliance Physician Registry
Gianfrancesco M, Leykina L, Izadi Z, Taylor T, Sparks J, Harrison C, Trupin L, Rush S, Schmajuk G, Katz P, Jacobsohn L, Hsu T, D’Silva K, Serling‐Boyd N, Wallwork R, Todd D, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Wallace Z, Machado P, Robinson P, Yazdany J, Alliance T. Association of Race and Ethnicity With COVID‐19 Outcomes in Rheumatic Disease: Data From the COVID‐19 Global Rheumatology Alliance Physician Registry. Arthritis & Rheumatology 2021, 73: 374-380. PMID: 33146001, PMCID: PMC8467766, DOI: 10.1002/art.41567.Peer-Reviewed Original ResearchConceptsRheumatic diseasesGeneral US populationRace/ethnicityVentilatory supportLatinx patientsOdds ratioUS populationCOVID-19Rheumatic disease activityRheumatic disease diagnosisOdds of hospitalizationAfrican American patientsAssociation of raceCOVID-19 outcomesPhysician registryCoronavirus disease 2019COVID-19 hospitalizationMultivariable regression modelsSignificant health disparitiesNeeds of patientsInequitable health outcomesDisease activityHospitalized patientsMedication useWhite patients
2020
Characteristics associated with Covid-19 in patients with Rheumatic Disease in Latin America: data from the Covid-19 Global Rheumatology Alliance physician-reported registry
Ugarte-Gil M, Marques C, Alpizar-Rodriguez D, Pons-Estel G, Xibille-Friedmann D, Paiva E, Zamora-Tehozol E, Gamboa-Cárdenas R, Quintana R, Rodriguez-Reyna T, Sepúlveda A, Gianfrancesco M, Evans M, Wallace Z, Sirotich E, Omedo E, Hausmann J, Alarcón G, Robinson P, Yazdany J. Characteristics associated with Covid-19 in patients with Rheumatic Disease in Latin America: data from the Covid-19 Global Rheumatology Alliance physician-reported registry. Global Rheumatology 2020 DOI: 10.46856/grp.10.e003.Peer-Reviewed Original ResearchOdds ratioRheumatic diseasesConfidence intervalsCharacteristics of patientsSystemic lupus erythematosusMultivariable logistic regressionFrequent rheumatic diseasesCOVID-19 diagnosisVentilatory supportLupus erythematosusRheumatoid arthritisDisease featuresPatientsLogistic regressionCOVID-19T-testMortalityDiseaseGroupErythematosusComorbiditiesHospitalizationArthritisRegistryPhysiciansSwinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19
Sattui S, Liew J, Graef E, Coler-Reilly A, Berenbaum F, Duarte-García A, Harrison C, Konig M, Korsten P, Putman M, Robinson P, Sirotich E, Ugarte-Gil M, Webb K, Young K, Kim A, Sparks J. Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert Review Of Clinical Immunology 2020, 16: 659-666. PMID: 32620062, PMCID: PMC7594186, DOI: 10.1080/1744666x.2020.1792778.Peer-Reviewed Original ResearchCharacteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
Gianfrancesco M, Hyrich K, Al-Adely S, Carmona L, Danila M, Gossec L, Izadi Z, Jacobsohn L, Katz P, Lawson-Tovey S, Mateus E, Rush S, Schmajuk G, Simard J, Strangfeld A, Trupin L, Wysham K, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Wallace Z, Yazdany J, Machado P, Robinson P. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals Of The Rheumatic Diseases 2020, 79: 859-866. PMID: 32471903, PMCID: PMC7299648, DOI: 10.1136/annrheumdis-2020-217871.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnti-Inflammatory Agents, Non-SteroidalAntimalarialsAntirheumatic AgentsArthritis, PsoriaticArthritis, RheumatoidBetacoronavirusBiological ProductsCoronavirus InfectionsCOVID-19FemaleGlucocorticoidsHospitalizationHumansJanus Kinase InhibitorsLupus Erythematosus, SystemicMaleMiddle AgedMultivariate AnalysisPandemicsPneumonia, ViralPrednisoneProtective FactorsRegistriesRheumatic DiseasesRisk FactorsSARS-CoV-2Severity of Illness IndexSpondylarthropathiesTumor Necrosis Factor InhibitorsVasculitisYoung AdultConceptsDisease-modifying antirheumatic drugsRheumatic diseasesHospitalisation statusHigher oddsNon-steroidal anti-inflammatory drug useConventional disease-modifying antirheumatic drugsAnti-inflammatory drug useOdds of hospitalisationRheumatic disease diagnosisRheumatic disease medicationsMultivariable-adjusted modelsMultivariable logistic regressionJanus kinase inhibitorCOVID-19 outcomesCOVID-19Prednisone doseAntirheumatic drugsGlucocorticoid exposureInhibitor useAntimalarial useClinical factorsCase seriesSmoking statusReduced oddsDecreased odds